Navigation Links
Hormone therapy increases frequency of abnormal mammograms, breast biopsies
Date:2/25/2008

Combined hormone therapy appears to increase the risk that women will have abnormal mammograms and breast biopsies and may decrease the effectiveness of both methods for detecting breast cancer, according to a report in the February 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Hormone therapy use remains common among women beginning menopause, according to background information in the article. For women with a uterus considering combined estrogen plus progestin use, identified breast cancer issues represent a concern, the authors write.

Rowan T. Chlebowski, M.D., Ph.D., of the Los Angeles Biomedical Research Institute at HarborUCLA Medical Center, and colleagues studied 16,608 post-menopausal women who participated in the Womens Health Initiative (WHI) clinical trial, beginning in 1993 through 1998. A total of 8,506 women were randomly assigned to receive a combination of estrogen (0.625 milligrams of conjugated equine estrogens per day) plus progesterone (2.5 milligrams of medroxyprogesterone acetate per day), while 8,102 took a placebo. Each woman received a mammogram and breast examination yearly, with biopsies performed based on physicians clinical judgment.

During the 5.6 years of the study, 199 women in the combined hormone group and 150 women in the placebo group developed breast cancer. Mammograms with abnormal results were more common among women taking hormones than among women taking placebo (35 percent vs. 23 percent); women taking hormones had a 4 percent greater risk of having a mammogram with abnormalities after one year and an 11 percent greater risk after five years.

Breast biopsies also were more common among women taking hormones than among those assigned to placebo (10 percent vs. 6.1 percent). Although breast cancers were significantly increased and were diagnosed at higher stages in the combined hormone group, biopsies in that group less frequently diagnosed cancer (14.8 percent vs. 19.6 percent), the authors write.

After discontinuation of combined hormone therapy, its adverse effect on mammograms modulated but remained significantly different from that of placebo for at least 12 months, they continue.

Use of combined hormones increases breast density, which increases the risk of breast cancer and may also delay diagnosis, the authors note. However, breast density was not measured in the current study.

Use of conjugated equine estrogens plus medroxyprogesterone acetate for approximately five years resulted in more than one in 10 and one in 25 women having otherwise avoidable mammogram abnormalities and breast biopsies, respectively, and compromised the diagnostic performance of both, the authors conclude. This adverse effect on breast cancer detection should be incorporated into risk-benefit discussions with women considering even short-term combined hormone therapy.


'/>"/>

Contact: Laura Mecoy
310-546-5860
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies
2. Hormone refractory prostate cancers more likely to spread to other organs
3. Newly discovered role of thyroid hormone during pregnancy
4. Stress hormone impacts memory, learning in diabetic rodents
5. Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor modulators
6. Diabetes, Growth Disorders Drive Sales of Pediatric Hormone Drugs
7. Sex Hormones Dont Seem to Affect Prostate Cancer Risk
8. Hormone Therapy Only Helps Some Older Men With Prostate Cancer
9. FDA Warns Against Bio-Identical Hormone Therapy
10. FDA Asserts New Policy to Restrict Womens Access to Bioidentical Hormones
11. Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2017)... CANADA (PRWEB) , ... July 22, 2017 , ... ... offer patients with irreparable rotator cuff repairs the opportunity to return to sports ... the American Orthopaedic Society for Sports Medicine’s Annual Meeting in Toronto, ...
(Date:7/21/2017)... ... ... The Ellis Agency, an eastern Georgie provider of insurance management and financial ... event with the goal of bringing in support for epilepsy patients in the greater ... recently launched a charity campaign of her own by donating her birthday to the ...
(Date:7/21/2017)... Long Grove, Ill. (PRWEB) , ... July 21, 2017 , ... ... Air & Fabric Liquid eco-friendly odor-control solution for colleges and universities at the ... to safely and effectively eliminate severe cannabis and tobacco smoke odors without the use ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... The Margarian ... falsely advertising the contents of its ginger ale for allegedly containing no ginger. Dr. ... Dr. Pepper Snapple Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing ... tie their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation ... launches on Kickstarter on Monday, July 21st. , The kit uses colorful, engaging ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... July 13, 2017  New York City-based market research firm ... should be aware of.  From new products to new costs, ... in a recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact ... aware of the impact the growing population and, to a ...
(Date:7/11/2017)... , July 11, 2017  The global market ... revenues of approximately $394.1 million in 2016.  Although in ... of solid growth, in particular as a result of ... practice, and the recent introduction of a significant number ... for less-invasive testing of tumor biomarkers to guide treatment ...
(Date:7/10/2017)... Md. , July 10, 2017 The ... non-animal test methods, is the recipient of a VITROCELL® ... the PETA International Science Consortium. The device, which is ... used to expose human lung cells to airborne test ... IIVS will use the VITROCELL® system for testing combustible ...
Breaking Medicine Technology: